In yesterday’s Wall Street session, Haleon plc ADR (NYSE:HLN) shares traded at $8.28, down -0.72% from the previous session.
HLN stock price is now -0.52% away from the 50-day moving average and -0.35% away from the 200-day moving average. The market capitalization of the company currently stands at $37.81B.
On November 01, 2023, Morgan Stanley recently initiated its ‘Overweight’ rating on the stock quoting a target price of $9, while ‘Stifel’ rates the stock as ‘Hold’
A total of 0.00% of the company’s stock is owned by insiders.
During the past 12 months, Haleon plc ADR has had a low of $7.70 and a high of $9.05. As of last week, the company has a debt-to-equity ratio of 0.57, a current ratio of 1.04, and a quick ratio of 0.73. The fifty day moving average price for HLN is $8.32 and a two-hundred day moving average price translates $8.31 for the stock.
The latest earnings results from Haleon plc ADR (NYSE: HLN) was released for Dec, 2023. For the current quarter, analysts expect HLN to generate $3.72B in revenue.
Haleon plc ADR(HLN) Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
